Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancer

Clinical Trial ID NCT05266820

Rank	Title	Journal	Year	PubWeight™‹?›
1	Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.	Cancer Res	1997	7.95
2	Randomized trial of TAS-102 for refractory metastatic colorectal cancer.	N Engl J Med	2015	3.09
3	The thalidomide saga.	Int J Biochem Cell Biol	2007	1.39
4	ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.	Ann Oncol	2016	1.34
5	Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial.	Clin Transl Oncol	2016	0.75
6	Enantiomers of thalidomide: blood distribution and the influence of serum albumin on chiral inversion and hydrolysis.	Chirality	1998	0.75
7	Efficacy of Thalidomide in Preventing Delayed Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Trial (CLOG1302 study).	J Clin Oncol	2017	0.75
8	Rechallenge and maintenance therapy using cetuximab and chemotherapy administered to a patient with metastatic colorectal cancer.	BMC Cancer	2017	0.75